NCT01586858

Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study

Rituximab for Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis (RAVE) Long-Term Follow-Up Study

• Status: Terminated
• Phase: —
• Study type: Observational
• Enrollment: 67 (actual)
• Sponsor: Johns Hopkins University · Academic / Other
• Sex: All
• Age: 12 Years – 100 Years
• Healthy volunteers: Not accepted

Summary

Rituximab is the first drug approved by the United States Food and Drug Administration (FDA) for the treatment of patients with granulomatosis with polyangiitis (Wegener's granulomatosis) or microscopic polyangiitis. Because it is a relatively new medication, the long-term safety and efficacy of this drug is not yet clear. This study proposes to follow patients who were enrolled in the RAVE study to determine if treatment with rituximab influences long-term outcomes.

Conditions

• Granulomatosis With Polyangiitis
• Microscopic Polyangiitis

Interventions

Type	Name	Description
OTHER	Observational	Observational study of subjects previously enrolled in the RAVE trial

Timeline

• Start date: 2012-05-01
• Primary completion: 2014-05-15
• Completion: 2014-05-15
• First posted: 2012-04-27
• Last updated: 2017-10-27

Locations

8 sites across 2 countries: United States, Netherlands